Volume 15 Supplement 1
Interstitial expansion in pressure overload left ventricular hypertrophy
© Treibel et al; licensee BioMed Central Ltd. 2013
Published: 30 January 2013
Diffuse myocardial fibrosis (DMF) is an important factor in cardiac disease, but until recently could only be accurately assessed with biopsy. We hypothesised that DMF measured by Equilibrium contrast CMR (EQ-CMR) is elevated in cardiac pressure overload (hypertension and aortic stenosis), that the degree of DMF will track the clinical severity of pressure overload and cardiac effects, and as such DMF may be a key biomarker in assessing the cardiac effects of pressure overload.
ECV measurement was by EQ-CMR. The T1 mapping sequence was ShMOLLI. The contrast agent was Gadoterate meglumine (Dotarem) at 0.1mmol/Kg (bolus) plus infusion at 15 minutes at 0.0011 mmol/kg/min. CMR was at 1.5T (Siemens Avanto):
ECV = (1-hematocrit)x (1/T1)myo ÷ (1/T1)blood.
ECV was measured in 43 patients with isolated, well-controlled hypertension (median age 56, range 21 to 78, 55% male), 28 patients with severe aortic stenosis (AS) undergoing aortic valve replacement (median age 70, range 60 to 84, 71% male), and 50 healthy volunteers (median age 47, range 28 to 69, 58% male).
The myocardial ECV increases with the degree of left ventricular pressure overload hypertrophy.
British Heart Foundation; National Institute for Health Research.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.